Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Galecto Reports Prelim. Topline Results From Trial Of Co.’s Inhaled Galectin-3 Inhibitor: ‘significantly reduced oxygen flow requirements and improved several biomarkers for lung and systemic inflammation, liver function, tissue damage and coagulation’

GB0139 significantly reduced oxygen flow requirements and improved several biomarkers for lung and systemic inflammation, liver function, tissue damage and coagulation Data demonstrate potential of GB0139 in

GLTO